Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep694 | Pituitary: basic and neuroendocrinology | ECE2015

Single dose irradiation of GH3 cells increase GH and PRL secretion in vitro

Fratticci Amato , Rotondi Sandra , Modarelli Alessio , Bonfili Pierluigi , Cesare Ernesto Di , Alesse Edoardo , Jaffrain-Rea Marie-Lise

Radiotherapy (RT) may represent a useful tool in the treatment of GH-secreting tumours in the presence of a post-operative active disease and single dose stereotactic RT/gamma knife is the preferred option in most cases. The effects of RT on the control of hormone secretion are very slow and pharmacological treatment remains necessary for years. Some authors advocate withdrawal of somatostatin analogues (SSA) during RT, although the short-term effects of RT on hormone secretio...

ea0014p153 | (1) | ECE2007

The beta-HLH transcription factor neurogenin-2 is preferentially expressed by secreting pituitary adenomas

Fratticci Amato , Grieco Fabio , Spilioti Cristina , Giangaspero Felice , Esposito Vincenzo , Santoro Antonio , Ventura Luca , Alesse Edoardo , Jaffrain-Rea Marie-Lise

Beta-HLH transcription factors are involved in the ontogenesis of neural/neuroendocrine cells, and may play a role in the pathogenesis of neuroendocrine tumours. Neurogenin 2 (Ngn2) is expressed by the developing mouse pituitary. After preliminary data indicating its expression in the normal human pituitary, we have studied its phenotypic expression in normal and adenomatous pituitary tissues.Methods: Fifty-two pituitary adenomas (PA) – 23 clinicall...

ea0022h1.3 | Oral Communications Highlights 1 | ECE2010

ESE Young Investigator Award

Libe Rossella , Horvath Anelia , Fratticci Amato , Vezzosi Delphine , Coste Joel , Guillaud-Bataille Marine , Groussin Lionel , Clauser Eric , Sanson Marie Laure Raffin , Bertagna Xavier , Stratakis Constantine , Bertherat Jerome

Background: Cushing syndrome due to PPNAD is the main endocrine disorder of CNC, an autosomal dominant multiple neoplasia caused by germline inactivating mutations of the subunit type 1A (PRKAR1A) of the protein kinase A (PKA). In addition, germline inactivating mutations in the gene encoding phosphodiesterase 11A (PDE11A) have been identified in patients with PPNAD.Aim of the study: To investigate the role of PDE11A genetic alterati...

ea0016s14.3 | Basic highlights | ECE2008

Variants of the phosphodiesterase 11A (PDE11A4) gene and genetic predisposition to adrenocortical tumors (ACT)

Libe Rossella , Fratticci Amato , Coste Joel , Groussin Lionel , Horvath Anelia , Rene-Corail Fernande , Bertagna Xavier , Raffin Sanson Marie-Laure , Stratakis Constantine , Bertherat Jerome

Introduction: We have previously identified (using a whole-genome large scale SNP- screening approach) germline inactivating stop codon mutations of the PDE11A4 in patients with Cushing syndrome due to micronodular adrenal hyperplasia. PDE11A4 is a cAMP/cGMP phosphodiesterase.Aim of the study: To investigate the role of PDE11A genetic alterations in a large cohort of ACT.Materials and methods: Leukocyte DNA from 117 adrenocortical ...